What could be the first chapter in a sequel to the Jumpstart Our Business Startups (JOBS) Act was unveiled Wednesday with the hope that it soon will become a congressional best-seller that will stimulate investment in groundbreaking R&D.
The FDA’s partial clinical hold on CUDC-427 because of a cancer patient’s death from liver failure overshadowed third-quarter earnings for Curis Inc., which is analyzing possible causes.
Vivus Inc. reported disappointing sales for its obesity drug Qsymia (phentermine/topiramate), driving its stock price down more than 12 percent. The drug brought in $6.4 million in net revenue in the third quarter of 2013, missing consensus estimates of $12 million by a wide margin. The company’s net loss for the quarter was $48 million, or 48 cents per share, compared to a net loss of $40.4 million, or 40 cents per share, in the third quarter of 2012.
VIENNA – It may be pushing the concept of pathetic fallacy a little hard to suggest that the early morning sunshine greeting delegates filing into the Wien Exhibition & Congress Center for the final day of BIO-Europe represented a new dawn for European biotechnology.
Scientists have identified an enzyme whose function is important for the survival of tuberculosis bacteria regardless of whether they are currently dividing or not.
• Immunocore Ltd., of Oxford, UK, said it reached the first milestone in the multitarget research and licensing agreement with London-based Glaxosmithkline plc to develop immunotherapeutics based on its ImmTac monoclonal T-cell receptor technology.
Cytori Therapeutics Inc. shares (NASDAQ:CYTX) headed skyward Tuesday morning after the company disclosed a deal with Chinese firm Lorem Vascular to commercialize Cytori cell therapy in the cardiovascular, renal and diabetes markets in China, Hong Kong, Malaysia, Singapore and Australia.
LONDON – Midatech Ltd. is poised to move its gold nanoparticle delivery technology into Phase II after raising £10 million (US$16 million) in its first formal round, and attracting Ippon Capital SA as a new investor with a commitment of £7.6 million.
RSS